Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M762Revenue $M17.3Net Margin (%)-207.9Z-Score3.9
Enterprise Value $M665EPS $-0.6Operating Margin %-197.3F-Score4
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-207.9Higher ROA y-yN
Price/Book9.210-y EBITDA Growth Rate %-7.6Quick Ratio2.7Cash flow > EarningsY
Price/Sales36.05-y EBITDA Growth Rate %7.3Current Ratio2.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-45.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-114.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M71.9ROI % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 10.6110%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 10.610%New holding, 59700 sh.59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sheridan William PSenior VP - CMO 2014-12-30Sell128,399$12.36-14.16view
STAAB THOMAS R IISenior Vice President and CFO 2014-12-29Sell9,500$12.56-15.53view
STAAB THOMAS R IISenior Vice President and CFO 2014-08-27Sell10,000$13.58-21.87view
STAAB THOMAS R IISenior Vice President and CFO 2014-07-01Sell3,125$13-18.38view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-23Sell3,125$12.49-15.05view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-17Sell3,125$12-11.58view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-14Sell3,125$11.24-5.6view
LEE KENNETH B JRDirector 2014-03-06Sell12,665$12.69-16.39view
Babu Yarlagadda SSenior VP - Drug Discovery 2014-03-04Sell40,642$12.57-15.59view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-04Sell3,000$12.69-16.39view

Press Releases about BCRX :

    Quarterly/Annual Reports about BCRX:

    News about BCRX:

    Articles On GuruFocus.com
    comment on BCRX Mar 02 2013 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

    More From Our Partners
    UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Jan 22 2015 - ZACKS

    More From Other Websites
    Equity markets ended little changed... Jan 26 2015
    Special FDA designation puts more wind behind BioCryst's sails Jan 26 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 26 2015
    6:59 am BioCryst Pharm announces that the FDA has granted Fast Track designation for BCX4161 for the... Jan 26 2015
    FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema Jan 26 2015
    Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape Jan 23 2015
    UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Jan 22 2015
    Flamel Technologies (FLML) in Focus: Stock Gains 15.4% - Tale of the Tape Jan 19 2015
    BioCryst's BCX4161 Recommended for Orphan Drug in EU - Analyst Blog Jan 15 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 14 2015
    BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment... Jan 14 2015
    BioCryst shares rally on positive opinion from Europe for angioedema drug Jan 14 2015
    BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment... Jan 14 2015
    Chimerix tackles Ebola outbreak Jan 13 2015
    BioCryst to Present at J.P. Morgan Healthcare Conference Jan 06 2015
    BioCryst to Present at J.P. Morgan Healthcare Conference Jan 06 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2015
    BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer Jan 05 2015
    BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer Jan 05 2015
    BioCryst Hits Trifecta For Flu, Ebola, and Hereditary Angioedema Dec 26 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK